CoChat

Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial

Open access
Droogendijk, Helga J., Kluin‐Nelemans, Hanneke J. C., van Doormaal, Jaap J., Oranje, Arnold P., van de Loosdrecht, Arjan A., van Daele, Paul L. A. · 2006 · Cancer
Cited by 147

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND.: Mastocytosis is characterized by the abnormal proliferation of mast cells in 1 or more organs. In most patients, a mutation is present in the gene for C‐KIT, resulting in deregulation of the c‐kit receptor. Imatinib mesylate is a potent inhibitor of c‐kit receptor tyrosine kinase activity. Therefore, the authors evaluated the efficacy and safety of imatinib mesylate as treatment for patients with systemic mastocytosis. METHODS.: Patients with systemic mastocytosis received imatinib mesylate orally at a dose of 400 mg once daily for 3 to 6 months. Low doses of prednisone were added during the first 2 weeks. Endpoints were reductions in serum tryptase, urinary N‐methylhistamine excretion, skin lesions, the number of mast cells in bone marrow sections, hepatomegaly and/or splenomegaly, and symptoms. RESULTS.: Of 14 patients who were included in the study, 11 patients had the D816V mutation. One patient expressed the FIP1L1‐PDGFR‐α rearrangement gene. In 2 patients, no mutation was found. In 10 patients, serum tryptase levels decreased >20%. In all patients, urinary N‐methylhistamine excretion was reduced. In 8 of 13 evaluable patients, the number of mast cells in the bone marrow decreased. Skin symptoms diminished in 5 of 9 patients. Hepatosplenomegaly improved in 3 of 6 patients. Symptoms decreased in 8 of 13 patients. In all patients who had the D816V mutation, reductions in ≥2 endpoints were achieved. In the patient who expressed the FIP1L1‐PDGFR‐α rearrangement gene, a complete response was attained. In general, imatinib mesylate was tolerated well. CONCLUSIONS.: Imatinib mesylate was effective in patients with systemic mastocytosis, including those who had the D816V mutation. Cancer 2006. © 2006 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.21996

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 147

Metadata

Authors
Droogendijk, H. J., Kluin‐Nelemans, H. J. C., van Doormaal, J. J., Oranje, A. P., van de Loosdrecht, A. A., & van Daele, P. L. A.
Venue
Cancer
Publisher
Wiley
Published
2006-07-05
Volume
107
Issue
2
Pages
345-351
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2137549989
Cited by
147
References
1
FWCI
3.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.